Review Article
Timolol 0.1% in Glaucomatous Patients: Efficacy, Tolerance, and Quality of Life
Table 2
Comparison of the data between baseline and the follow-up by using ANOVA test and the Bonferroni post hoc test.
| ā | Baseline | 1 month | 3 months | Baseline vs. 1 month | 1 month vs. 3 months | Baseline vs. 3 months | Mean (SD) | Mean (SD) | Mean (SD) | value | value | value |
| Eyelid erythema | 0.46 (0.82) | 0.23 (0.55) | 0.13 (0.37) | <0.001 | <0.001 | <0.001 | Conjunctival hyperaemia | 0.97 (0.94) | 0.58 (0.64) | 0.33 (0.52) | <0.001 | <0.001 | <0.001 | Follicular hyperplasia | 0.36 (0.62) | 0.16 (0.40) | 0.08 (0.31) | <0.001 | <0.001 | <0.001 | Beak-up time (sec) | 9.82 (0.31) | 10.9 (3.24) | 11.5 (3.38) | <0.001 | <0.001 | <0.001 | Schirmer test (min) | 13.46 (6.28) | 14.72 (6.44) | 15.41 (6.32) | <0.001 | <0.001 | <0.001 |
|
|
|